Myocardial disease in human immunodeficiency virus (HIV) infection: a review.
Heart muscle disease is the most important cardiovascular manifestation of HIV infection and is likely to become even more prevalent as HIV infected patients live longer. This may present as myocarditis, dilated cardiomyopathy or isolated left or right ventricular dysfunction. Myocardial involvement in HIV infection is multifactorial and may arise as a result of myocardial invasion with HIV itself, opportunistic infections, viral infections, autoimmune response to viral infection, drug-related cardiac toxicity, nutritional deficiencies, and prolonged immunosuppression. Both adults and children are affected with severity ranging from incidental microscopic inflammatory findings at autopsy to clinically significant cardiac disease with chronic cardiac dysfunction. It is associated with a poor prognosis, and results in symptomatic heart failure in up to 5% of HIV patients. Clinical pathological studies from the pre-HAART era show a 30% prevalence of cardiomyopathy in patients with AIDS. The introduction of highly active antiretroviral therapy (HAART) regimens has substantially modified the course of HIV disease by lengthening survival and improving quality of life of HIV-infected patients. There is also good evidence that HAART significantly reduces the incidence of cardiovascular manifestations of HIV infection. By preventing opportunistic infections and reducing the incidence of myocarditis, HAART regimens have reduced the prevalence of HIV-associated cardiomyopathy by almost 7-fold from the pre-HAART era. HAART is however only available to a minority of HIV infected individuals in most areas of the world and studies from the pre-HAART period still apply. In this review, the aetiopathogenesis and presentation of HIV related myocardial disease were reviewed and measures taken to improve survival discussed.
Sani
Mahmoud Umar
MU
Department of Medicine, Bayero University Kano, Kano, Nigeria. sanimahmoud@yahoo.com
D023241:Antiretroviral Therapy, Highly Active; D009202:Cardiomyopathies / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D009205:Myocarditis / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D011379:Prognosis; D018754:Ventricular Dysfunction / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology